Lixte Stock Today

LIXT -  USA Stock  

USD 2.79  0.13  4.89%

Lixte Biotech is selling for under 2.79 as of the 29th of July 2021; that is 4.89 percent up since the beginning of the trading day. The stock's last reported lowest price was 2.69. Lixte Biotech has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Lixte Biotech Hlds are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of June 2021 and ending today, the 29th of July 2021. Click here to learn more.
 Market Performance
1 of 100
  Odds Of Distress
Over 97
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Lixte Biotech Stock Profile

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was incorporated in 2005 and is based in East Setauket, New York. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. more on Lixte Biotech
Lixte Biotech Hlds has very high historical volatility over the last 90 days
Lixte Biotech Hlds has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 200 K. Net Loss for the year was (4.61 M) with profit before overhead, payroll, taxes, and interest of 0.
Lixte Biotech Hlds currently holds about 7.74 M in cash with (2.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.57.
Roughly 68.0% of the company outstanding shares are owned by corporate insiders
Latest headline from MacroaxisInsider: Lixte Biotech exotic insider transaction detected
Legal NameLixte Biotech Hlds
CEO, CFO, DirectorJohn Kovach  (View All)
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Lixte Biotech's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
Lixte Biotech Hlds (LIXT) is traded on NASDAQ Exchange in USA and employs 3 people. The company currently falls under 'Micro-Cap' category with current market capitalization of 37.91 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lixte Biotech's market, we take the total number of its shares issued and multiply it by Lixte Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Lixte Biotech Hlds conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 13.54 M outstanding shares of which 29.88 K shares are now shorted by private and institutional investors with about 0.06 trading days to cover. Lixte Biotech Hlds currently holds about 7.74 M in cash with (2.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.57.
Check Lixte Biotech Probability Of Bankruptcy
Ownership
Lixte Biotech Hlds holds a total of 13.54 Million outstanding shares. Lixte Biotech Hlds secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company outstanding shares. 67.85 % of Lixte Biotech Hlds outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Lixte Ownership Details

Lixte Stock Price Odds Analysis

What are Lixte Biotech's target price odds to finish over the current price? Attributed to a normal probability distribution, the odds of Lixte Biotech jumping above the current price in 90 days from now is about 70.17%. The Lixte Biotech Hlds probability density function shows the probability of Lixte Biotech stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Lixte Biotech has a beta of 0.3355. This indicates as returns on the market go up, Lixte Biotech average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Lixte Biotech Hlds will be expected to be much smaller as well. Additionally, the company has an alpha of 0.2061, implying that it can generate a 0.21 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 2.79HorizonTargetOdds Up 2.79 
29.64%90 days
 2.79 
70.17%
Based on a normal probability distribution, the odds of Lixte Biotech to move above the current price in 90 days from now is about 70.17 (This Lixte Biotech Hlds probability density function shows the probability of Lixte Stock to fall within a particular range of prices over 90 days) .

Lixte Biotech Hlds Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Lixte Biotech market risk premium is the additional return an investor will receive from holding Lixte Biotech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Lixte Biotech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Lixte Biotech's alpha and beta are two of the key measurements used to evaluate Lixte Biotech's performance over the market, the standard measures of volatility play an important role as well.

Lixte Stock Against Markets

Picking the right benchmark for Lixte Biotech stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Lixte Biotech stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Lixte Biotech is critical whether you are bullish or bearish towards Lixte Biotech Hlds at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Lixte Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Analyst Recommendations Now

   

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Module

Lixte Biotech Corporate Directors

Lixte Biotech corporate directors refer to members of a Lixte Biotech board of directors. The board of directors generally takes responsibility for the Lixte Biotech's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Lixte Biotech's board members must vote for the resolution. The Lixte Biotech board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Stephen Forman - DirectorProfile
Kathleen Mullinix - Independent DirectorProfile
Philip Palmedo - Independent DirectorProfile
Winson Ho - DirectorProfile
Additionally, see Stocks Correlation. Note that the Lixte Biotech Hlds information on this page should be used as a complementary analysis to other Lixte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Lixte Stock analysis

When running Lixte Biotech Hlds price analysis, check to measure Lixte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotech is operating at the current time. Most of Lixte Biotech's value examination focuses on studying past and present price action to predict the probability of Lixte Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lixte Biotech's price. Additionally, you may evaluate how the addition of Lixte Biotech to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
The market value of Lixte Biotech Hlds is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotech's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotech's market value can be influenced by many factors that don't directly affect Lixte Biotech Hlds underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Lixte Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.